

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | |
|----------------------|------------------|
| Application Number | 10/041,556 |
| Filing Date | January 10, 2002 |
| First Named Inventor | Wilfried Lubisch |
| Group Art Unit | 1624 |
| Examiner Name | COLEMAN |
| Attorney Docket No. | ABB10010P0690US |

Sheet 1 of 4

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
| | | Number Kind Code ² (if known) | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------------------|-----------------------|---|--------------------------------|---|--|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| BC | | WO 01/16136 A2 | March 8, 2001 | Agouron Pharmaceuticals, Inc. Cancer Research Campaign Technology Limited | | |
| BC | | WO 01/23390 A2 | April 5, 2001 | BASF Aktiengesellschaft | | |
| | | | | | | |
| | | | | | | |

Examiner Signature

Brenda Coleman


Date Considered

June 29, 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶Applicant is to place a checkmark here if English language Translation is attached.

** structures only

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



| | | | | | |
|--|---|----|---|----------------------|------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/041,556 |
| | | | | Filing Date | January 10, 2002 |
| | | | | First Named Inventor | Wilfried Lubisch |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | COLEMAN |
| Sheet | 3 | of | 4 | Attorney Docket No. | ABB10010P0690US |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|----------|---|----------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| BC | | BURKART, et al., Mice lacking the poly (ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin; March 1999, pp. 314-319; Vol. 5, No. 3, Nature Medicine | |
| BC | | CHEN, et al., Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide; (1998), pp. 303-307; Vol. 22, Cancer Chemotherapy and Pharmacology. | |
| BC | | EHRlich, et al., Inhibition of the induction of collagenase by interleukin 18 in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide; March 1995, pp. 171-172; Vol. 15; Rheumatol Int. | |
| BC | | GÄKEN, et al., Efficient Retroviral Infection of Mammalian Cells Is Blocked by Inhibition of Poly (ADP-Ribose) Polymerase Activity; June 1996; pp. 3992-4000; Vol. 70, No. 6; Journal of Virology | |
| BC | | CUZZOCREA, et al., Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion; 1997; pp. 1065-1074; Vol. 121; British Journal of Pharmacology | |
| BC | | CUZZOCREA, et al., Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation; 1998, pp. 67-76; Vol. 342; European Journal of Pharmacology | |
| BC | | IKAI, et al., Immunohistochemical Demonstration of Poly (Adenosine Diphosphate-Ribose) Synthetase in Bovine Tissues; 1983; pp. 1261-1264; Vol. 31, No. 11; The Journal of Histochemistry and Cytochemistry | |
| BC | | KRÖGER, et al., Synergistic Effects of Thalidomide and Poly(ADP-Ribose) Polymerase Inhibition on Type II Collagen-Induced Arthritis in Mice; 1996; pp. 203-215; Vol. 20, No. 2; Inflammation | |
| BC | | SHALL, SYDNEY; ADP-Ribose in DNA Repair; A New Component of DNA Excision Repair; 1984; pp. 1-65; Vol. II, Advances in Radiation Biology | |
| BC | | KAMEOKA, et al., Poly (ADP-ribose) Polymerase Is Involved in PMA-induced Activation of HIV-1 in U1 Cells by Modulating the LTR Function; 1999; pp. 285-289; Vol. 262; Biochemical and Biophysical Research Communications | |
| BC | | SATOH, et al., Role of poly(ADP-ribose) formation of DNA repair; March 1992; pp. 356-358; Vol. 356; Nature | |
| BC | | SZABÓ, et al., Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase; March 1998; 3867-3872; Vol. 95; Proc. Natl. Acad. Sci. USA | |
| BC | | WELTIN, et al., Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly (ADP-Ribose) Polymerase Inhibitor; 1995; pp. 265-271, Vol. 17, No. 4; Int. J. Immunopharmac | |

| | |
|--------------------|---|
| BC | THIEMERMANN, et al., Inhibition of the activity of poly (ADP ribose) synthetase reduces ischemia -reperfusion injury in the heart and skeletal muscle; January 1997; pp. 679-683; Vol. 94; Proc. Natl. Acad. Sci. USA |
| | |
| Examiner Signature | <div data-bbox="337 262 714 310" data-label="Text">Brenda Coleman</div> <div data-bbox="1003 289 1136 310" data-label="Text">Date Considered</div> <div data-bbox="1198 262 1502 310" data-label="Text">June 29, 2004</div> |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.